General Area of Claim
Use of Anti-Prolactin Agents to Treat Cancer/Proliferative Conditions
Use of Prolactin Receptor Antagonists in Combination with an Agent that Inactivates the HER2/Neu signaling Pathway
Compositions and Methods for Visualizing and Eliminating Cancer Stem Cells (Ovarian Cancer Claims)
United Kingdom 2400979
Human Prolactin Antagonist-Angiogenesis Inhibitor Fusion Proteins
US 8,304, 381
Multimeric Ligands with Enhanced Stability
United Kingdom 2385132
United Kingdom 1576097
Use of Prolactin in the Prophylactic Treatment of Cancer
United Kingdom 1579985
Bi-Functional Cancer Treatment Agents
In addition to patents, Prolanta has received orphan designation from the US FDA for the treatment of ovarian cancer, which provides for seven years of market exclusivity. Oncolix intends to apply for orphan designation in the EU and Japan to treat ovarian cancer, both which provide for 10 years of market exclusivity.
Furthermore, under the US Affordable Care Act in the United States, biologicals such as Prolanta are granted 12 years of market exclusivity.